Epicrispr Biotechnologies to Begin Clinical Trials for its Lead Epigenetic Therapy for FSHD Patients
The therapy, EPI-321, is intended to treat cases of facioscapulohumeral muscular dystrophy, a genetic neuromuscular disorder.
Clinical Trials Arena on MSN17h
Epicrispr secures $68m for facioscapulohumeral muscular dystrophy therapy trialEpicrispr Biotechnologies has raised $68m in the initial close of its Series B financing round to commence the clinical trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback